The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
May 1st 2025
Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective VEGF inhibition.
New Cancer Research Collaboration Seeks to Develop Targeted Radium Therapeutic
February 23rd 2021Pharmacy Times® interviewed J. David Robertson, PhD, director of University of Missouri Research Reactor, on a new collaboration with Advanced Accelerator Applications International to develop a targeted therapy for certain types of cancerous tumors.
Watch
FDA to Evaluate BLAs for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
February 19th 2021Two supplemental BLAs have been submitted to the FDA for enfortumab vedotin-ejfv to convert its accelerated approval into a regular one and to expand the current label to include patients with locally advanced or metastatic urothelial cancer.
Read More
Vicineum Granted FDA Priority Review for Non–Muscle Invasive Bladder Cancer
February 18th 2021The FDA granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Read More
Study: High Rate of Smoking Reduction, Cessation in Patients With Lung Cancer Following Study Entry
February 17th 2021A recent comprehensive, prospective study of smoking habits among patients with non-small cell lung cancer demonstrated a high rate of smoking reduction and cessation following entry into the phase 3 early-stage trial.
Read More
FDA Approves Treatment for Chemotherapy-Induced Bone Marrow Suppression in Small Cell Lung Cancer
February 15th 2021The FDA has approved trilaciclib (Cosela) to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.
Read More
FDA to Evaluate Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
February 11th 2021A biologics license application has been submitted to the FDA for the accelerated approval of tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.
Read More
More Than Half of American Adults with Multiple Sclerosis Report Mistreatment by Caregivers
February 10th 2021Patients with multiple sclerosis who rely on family members as caregivers may be at particular risk for mistreatment, as those caregivers struggle to balance work, childcare, and health concerns of their own.
Read More
FDA Grants Breakthrough Therapy Designations for Investigational STAMP inhibitor in CML
February 9th 2021The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.
Read More
FDA Approves Breyanzi for Adults with Relapsed, Refractory Large B-cell Lymphoma
February 8th 2021Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.
Read More
FDA Grants Accelerated Approval to Treatment for Marginal Zone Lymphoma, Follicular Lymphoma
February 8th 2021The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.
Read More
Study Finds Oral Azacitidine as AML Maintenance Treatment Prolongs Survival
February 3rd 2021Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.
Read More
First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer
February 2nd 2021The guidelines recommend discontinuing routine mammograms for survivors with a life expectancy under 5 years, considering stopping screening for those with a 5- to 10-year life expectancy, and continuing mammography for those whose life expectancy is greater than 10 years.
Read More